DiagnoCure's Q3 Revenues Shrink 12 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer diagnostics company DiagnoCure said on Thursday that revenues for its fiscal third quarter dropped 12 percent year over year.

For the three months ended July 31, the Quebec City-based firm posted C$304,288 (US$305,570) in revenues, down from C$347,130 a year ago. Research and licensing-related revenues were C$292,073 for the quarter, down from C$308,720 a year ago, while interest revenues fell to C$12,215 from C$38,410.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.